GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Rhea-AI Summary

GRI Bio (NASDAQ: GRI) has received a 'Decision to Grant' notice from the Japan Patent Office for patent application No. 2023-000750, titled 'Prevention and Treatment of Inflammatory Conditions.' The patent covers compositions and methods for modulating type 2 and/or type 1 invariant NKT (iNKT) cells in treating inflammatory, fibrotic, and autoimmune conditions through the administration of a Retinoic Acid Receptor (RAR) agonist.

Japan's pharmaceutical market, valued at approximately $106 billion in 2021, is the third largest worldwide. GRI Bio's lead program, GRI-0621, a small molecule RAR-βɣ dual agonist candidate, is currently in a Phase 2a study for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Interim data is expected in Q4 2024 and topline data in Q1 2025.

Positive

• Granted patent in Japan for NKT cell modulators in treating inflammatory conditions
• Potential access to Japan's $106 billion pharmaceutical market
• Lead program GRI-0621 in Phase 2a study for IPF treatment
• Interim data for GRI-0621 expected in Q4 2024, topline data in Q1 2025

Negative

• None.

Insights

Biotechnology Patent Expert

The granting of a patent in Japan for GRI Bio's NKT cell modulators is a significant development, albeit with immediate financial impact. This patent strengthens the company's intellectual property portfolio in a major pharmaceutical market, potentially enhancing future commercialization opportunities. The patent's broad coverage of compositions and methods for modulating NKT cells in inflammatory conditions aligns well with GRI Bio's pipeline focus. While this doesn't directly translate to near-term revenue, it does provide a competitive advantage and could be valuable for potential partnerships or licensing agreements in Japan. Investors should view this as a positive step in GRI Bio's long-term strategy, particularly considering Japan's $106 billion pharmaceutical market and the prevalence of target indications like IPF and SLE.

Clinical Research Analyst

GRI Bio's ongoing Phase 2a trial for GRI-0621 in IPF is the more immediate focus for investors. The expected interim data in Q4 2024 and topline data in Q1 2025 are critical milestones that could significantly impact the company's valuation. IPF is a severe condition with high unmet need and positive trial results could position GRI-0621 as a potential breakthrough therapy. The mechanism of action, targeting NKT cells, is innovative and differentiated from current standards of care. However, it's important to note that Phase 2 trials carry inherent risks and success is not guaranteed. Investors should closely monitor these upcoming data readouts as they will likely be more impactful on stock performance in the near term than the patent grant.

Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases

LA JOLLA, CA, Sept. 30, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced it has received a "Decision to Grant" notice from the Japan Patent Office (JPO) for the patent application No. 2023-000750 titled, “Prevention and Treatment of Inflammatory Conditions.”

The granted patent covers claims including compositions and methods for modulating type 2 and/or type 1 invariant NKT (iNKT) cells in the prevention and treatment of inflammatory conditions. More specifically, the patent covers the prevention and treatment of inflammatory, fibrotic and autoimmune conditions through the administration of a Retinoic Acid Receptor (RAR) agonist that inhibits iNKT cells in a subject.

Japan's pharmaceutical market was valued at approximately $106 billion in 2021, ranking as the third largest worldwide and accounting for about 7.2% of the global pharmaceutical market. This robust industry serves a population with a high life expectancy and an increasing prevalence of chronic diseases, including Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE). Published literature suggests the prevalence rates for IPF and SLE in Japan are similar to those for these diseases in the U.S. 

“Japan is a large and growing, multi-billion dollar pharmaceutical market with an increasing prevalence of chronic diseases, including our lead indications, IPF and SLE. We believe our highly differentiated approach represents a compelling opportunity to address unmet medical needs in the prevention and treatment of inflammatory, fibrotic and autoimmune diseases. As we continue to advance our pipeline of NKT cell modulators targeting these high-value indications, we are committed to bolstering our IP portfolio and are pleased to add Japan, a key territory with significant potential, to our global patent estate,” Marc Hertz, PhD, Chief Executive Officer of GRI Bio.

GRI Bio is currently advancing its lead program GRI-0621, a small molecule RAR-βɣ dual agonist candidate that inhibits the activity of human iNKT cells, in a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study for the treatment of IPF. IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream. Interim data is expected in Q4 2024 and topline data in Q1 2025.

For more information about the Company’s innovative pipeline of NKT cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases, visit gribio.com.

About GRI Bio, Inc.

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions. These forward-looking statements are based on the Company’s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the Company’s expectations with respect to development and commercialization of the Company’s product candidates, the timing of initiation or completion of clinical trials and availability of resulting data, potential acceleration of enrollment, the potential benefits and impact of the Company’s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials, the Company’s beliefs and expectations regarding potential stakeholder value and future financial performance, the Company’s beliefs about the timing and outcome of regulatory approvals and potential regulatory approval pathways, the Company’s expected milestones for 2024, including the potential availability of clinical trial data, and the Company’s beliefs and expectations regarding the sufficiency of its existing cash and cash equivalents to fund its operating expenses and capital expenditure requirements. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company’s common stock on Nasdaq and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company’s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company’s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) the failure to achieve any milestones or receive any milestone payments under any agreements; (10) inaccuracy in the Company’s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company’s ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (12) other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the risks and uncertainties described in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 28, 2024 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com

FAQ

What patent did GRI Bio (NASDAQ: GRI) receive in Japan?

GRI Bio received a 'Decision to Grant' notice from the Japan Patent Office for patent application No. 2023-000750, titled 'Prevention and Treatment of Inflammatory Conditions,' covering compositions and methods for modulating NKT cells in treating inflammatory, fibrotic, and autoimmune conditions.

What is GRI Bio's (NASDAQ: GRI) lead program and its current stage of development?

GRI Bio's lead program is GRI-0621, a small molecule RAR-βɣ dual agonist candidate. It is currently in a Phase 2a study for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

When does GRI Bio (NASDAQ: GRI) expect to release data for its lead program?

GRI Bio expects to release interim data for GRI-0621 in Q4 2024 and topline data in Q1 2025.

What is the size of the Japanese pharmaceutical market that GRI Bio (NASDAQ: GRI) could potentially access?

Japan's pharmaceutical market was valued at approximately $106 billion in 2021, ranking as the third largest worldwide and accounting for about 7.2% of the global pharmaceutical market.